Sign in to view content

Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics

David R Lally, MD

Video
Published 2021

Related

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Reached Statistical Significance in a Pivotal Clinical Trial for Geographic Atrophy Secondary to Dry AMD
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2020
Utility of Outer Retinal Tubulation in Predicting Lesion Growth in Subfoveal and Nonsubfoveal Geographic Atrophy
Srinivas Sai A Kondapalli, MD
Annual Meeting Talks
2023

Category: AMD-Non-Neovascular

See more